By group, 15 of 26 AML-MR samples (57.69%), four of 12 (33.33%) MDS-IB samples, and seven of 39 (17.95%) MDS-LB samples were found to have TP53 gene aberrations. The gene discussed is TP53; the disease is myelodysplastic syndrome.